Viatris(VTRS) Seeking Alpha·2025-01-24 22:25Investment Opportunities - The Haggerston BioHealth marketplace channel offers at least 4 exclusive stock tips weekly, focusing on Pharma, Biotech, and Healthcare sectors, alongside access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, providing catalysts, buy/sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis for Big Pharma companies [2] Company Overview - Viatris (NASDAQ: VTRS) was formed in 2020 through the merger of generics drug giant Mylan and Pfizer's Upjohn business [2] - The company's Q3 2024 earnings announcement was preceded by a detailed overview, highlighting its strategic position in the generics and pharmaceutical markets [2] Analyst Background - Edmund Ingham, a biotech consultant with over 5 years of experience covering biotech, healthcare, and pharma, leads the Haggerston BioHealth investing group [2] - He has compiled detailed reports on over 1,000 companies, providing in-depth insights into the biotech and healthcare sectors [2]